
Articles
-
2 weeks ago |
news.bloomberglaw.com | Eric Pfanner |Rachel Phua
Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the US-China trade dispute threatens its earnings. The unit will become a new publicly traded entity, with an initial public offering the favored route, according to a statement Wednesday. Diabetes accounted for about 8% of Medtronic’s $33.5 billion revenue in the latest fiscal year.
-
2 weeks ago |
news.bloombergtax.com | Eric Pfanner |Rachel Phua
XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
-
2 weeks ago |
modernhealthcare.com | Eric Pfanner |Rachel Phua
Breadcrumb Home Digital Health May 21, 2025 09:36 AM Tweet Share Share Email More Reprints Print Getty Images Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the U.S.-China trade dispute threatens its earnings.
-
2 weeks ago |
bloomberg.com | Eric Pfanner |Rachel Phua
(Bloomberg) -- Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the US-China trade dispute threatens its earnings. The unit will become a new publicly traded entity, with an initial public offering the favored route, according to a statement Wednesday. Diabetes accounted for about 8% of Medtronic’s $33.5 billion revenue in the latest fiscal year.
-
3 weeks ago |
bloomberglinea.com.br | Eric Pfanner
Bloomberg — A Novo Nordisk destituiu o CEO Lars Fruergaard Jorgensen enquanto a farmacêutica luta contra a crescente concorrência para seu tratamento de obesidade Wegovy, que tem pesado sobre o preço das ações. A empresa dinamarquesa disse que Jorgensen está saindo por acordo mútuo com o conselho, embora ele continue como chefe “por um período para apoiar uma transição suave para uma nova liderança”. A busca por um novo líder já começou, disse a empresa em um comunicado na sexta-feira (16).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 1K
- DMs Open
- No

RT @yunheekim22: Sharp shares plunge more than 10% after delay in Foxconn deal https://t.co/9Zd0gyRqIS via @ericpfanner

RT @WSJ: Why does Foxconn want Sharp? Here are the top five reasons https://t.co/bk4gCSVkEV https://t.co/v5JQZXeDiC

RT @evadou: Sharp has announced it picked Foxconn. INCJ has admitted it lost. Japan's govt has weighed in. Foxconn still silent. Hmmm...